GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Feedback PLC (LSE:FDBK) » Definitions » EV-to-EBITDA

Feedback (LSE:FDBK) EV-to-EBITDA : -0.20 (As of Sep. 22, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Feedback EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Feedback's enterprise value is £0.70 Mil. Feedback's EBITDA for the trailing twelve months (TTM) ended in Nov. 2023 was £-3.48 Mil. Therefore, Feedback's EV-to-EBITDA for today is -0.20.

The historical rank and industry rank for Feedback's EV-to-EBITDA or its related term are showing as below:

LSE:FDBK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.27   Med: -3.52   Max: 1.18
Current: -0.2

During the past 13 years, the highest EV-to-EBITDA of Feedback was 1.18. The lowest was -41.27. And the median was -3.52.

LSE:FDBK's EV-to-EBITDA is ranked worse than
100% of 482 companies
in the Healthcare Providers & Services industry
Industry Median: 12.465 vs LSE:FDBK: -0.20

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-22), Feedback's stock price is £0.455. Feedback's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2023 was £-0.261. Therefore, Feedback's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Feedback EV-to-EBITDA Historical Data

The historical data trend for Feedback's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feedback EV-to-EBITDA Chart

Feedback Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.11 -3.37 -4.60 -3.25 -3.07

Feedback Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Nov22 May23 Nov23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.25 - -3.07 -

Competitive Comparison of Feedback's EV-to-EBITDA

For the Health Information Services subindustry, Feedback's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Feedback's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Feedback's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Feedback's EV-to-EBITDA falls into.



Feedback EV-to-EBITDA Calculation

Feedback's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.695/-3.475
=-0.20

Feedback's current Enterprise Value is £0.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Feedback's EBITDA for the trailing twelve months (TTM) ended in Nov. 2023 was £-3.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Feedback  (LSE:FDBK) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Feedback's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.455/-0.261
=At Loss

Feedback's share price for today is £0.455.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Feedback's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2023 was £-0.261.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Feedback EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Feedback's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Feedback Business Description

Traded in Other Exchanges
N/A
Address
3-7 Temple Avenue, 201 Temple Chambers, London, GBR, EC4Y 0DT
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. The company also entered into a joint venture for future clinical application of its products on patients with kidney stones and it has a medical imaging segment.

Feedback Headlines

No Headlines